Literature DB >> 34256746

Association between dual use of e-cigarette and cigarette and chronic obstructive pulmonary disease: an analysis of a nationwide representative sample from 2013 to 2018.

Taeyun Kim1, Jihun Kang2.   

Abstract

BACKGROUND: The association between the dual use of electronic cigarette (e-cigarette) and conventional cigarettes (c-cigarette) and spirometry-defined chronic obstructive pulmonary disease (COPD) has not been studied thoroughly.
METHODS: A total of 47,217 participants were identified in the 2013-2018 Korea National Health and Nutrition Examination Survey; of them, 12,919 participants aged ≥ 40 who underwent spirometry and had no missing data were enrolled. Pulmonary function testing, urinary cotinine, and urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) levels were compared between dual users, current smokers, former smokers, and non-users using complex sample linear regression analysis. The odds ratio (OR) for COPD was calculated using a complex sample logistic regression model after adjusting for covariates.
RESULTS: Among current e-cigarette users, approximately 85% of the participants used c-cigarette concurrently, and 1.3% of all the participants were dual users (2.3% in males and 0.1% in females). Both dual users and current smokers showed higher levels of urine cotinine and NNAL than non-users and former smokers. The weighted prevalence of COPD was the highest in dual users (13.8% for all participants and 14.1% for males). The multivariate-adjusted OR of COPD for male dual users, compared to non-users, was 3.46 (Ptrend < 0.001). The OR for COPD was 3.10 (Ptrend < 0.001) in middle-aged (40-64 years) and 3.70 (Ptrend < 0.001) in older (≥ 65 years) men. In females, the association was not observed and could not be precisely measured because of the small proportion of the smoking population.
CONCLUSIONS: Dual use of e-cigarette and c-cigarette is associated with COPD in males.
© 2021. The Author(s).

Entities:  

Keywords:  COPD; Dual use; E-cigarette

Year:  2021        PMID: 34256746     DOI: 10.1186/s12890-021-01590-8

Source DB:  PubMed          Journal:  BMC Pulm Med        ISSN: 1471-2466            Impact factor:   3.317


  33 in total

1.  Electronic cigarette use in France in 2014.

Authors:  Raphaël Andler; Romain Guignard; Jean-Louis Wilquin; François Beck; Jean-Baptiste Richard; Viêt Nguyen-Thanh
Journal:  Int J Public Health       Date:  2015-12-21       Impact factor: 3.380

2.  Dual use of electronic cigarettes and tobacco in New Zealand from a nationally representative sample.

Authors:  Alana Oakly; Greg Martin
Journal:  Aust N Z J Public Health       Date:  2019-02-06       Impact factor: 2.939

Review 3.  Biomarkers of exposure to new and emerging tobacco delivery products.

Authors:  Suzaynn F Schick; Benjamin C Blount; Peyton Jacob; Najat A Saliba; John T Bernert; Ahmad El Hellani; Peter Jatlow; R Steven Pappas; Lanqing Wang; Jonathan Foulds; Arunava Ghosh; Stephen S Hecht; John C Gomez; Jessica R Martin; Clementina Mesaros; Sanjay Srivastava; Gideon St Helen; Robert Tarran; Pawel K Lorkiewicz; Ian A Blair; Heather L Kimmel; Claire M Doerschuk; Neal L Benowitz; Aruni Bhatnagar
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-05-18       Impact factor: 5.464

4.  Association of E-Cigarette Use With Respiratory Disease Among Adults: A Longitudinal Analysis.

Authors:  Dharma N Bhatta; Stanton A Glantz
Journal:  Am J Prev Med       Date:  2019-12-16       Impact factor: 5.043

Review 5.  Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema.

Authors:  Barbara A Forey; Alison J Thornton; Peter N Lee
Journal:  BMC Pulm Med       Date:  2011-06-14       Impact factor: 3.317

6.  COPD smokers who switched to e-cigarettes: health outcomes at 5-year follow up.

Authors:  Ricardo Polosa; Jaymin B Morjaria; Umberto Prosperini; Barbara Busà; Alfio Pennisi; Mario Malerba; Marilena Maglia; Pasquale Caponnetto
Journal:  Ther Adv Chronic Dis       Date:  2020-10-10       Impact factor: 5.091

Review 7.  COPD Guidelines: A Review of the 2018 GOLD Report.

Authors:  Shireen Mirza; Ryan D Clay; Matthew A Koslow; Paul D Scanlon
Journal:  Mayo Clin Proc       Date:  2018-10       Impact factor: 7.616

Review 8.  COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early intervention.

Authors:  Marc Decramer; Stephen Rennard; Thierry Troosters; Douglas W Mapel; Nicholas Giardino; David Mannino; Emiel Wouters; Sanjay Sethi; Christopher B Cooper
Journal:  COPD       Date:  2008-08       Impact factor: 2.409

9.  Chronic electronic cigarette exposure in mice induces features of COPD in a nicotine-dependent manner.

Authors:  Itsaso Garcia-Arcos; Patrick Geraghty; Nathalie Baumlin; Michael Campos; Abdoulaye Jules Dabo; Bakr Jundi; Neville Cummins; Edward Eden; Astrid Grosche; Matthias Salathe; Robert Foronjy
Journal:  Thorax       Date:  2016-08-24       Impact factor: 9.139

10.  High prevalence of chronic obstructive pulmonary disease in Korea.

Authors:  Chin Kook Rhee
Journal:  Korean J Intern Med       Date:  2016-07-01       Impact factor: 2.884

View more
  3 in total

1.  Association between a History of herpes zoster and the risk of Sjögren's syndrome: a nationwide, population-based, case-control study.

Authors:  Pei Ju Huang; Shih-Ping Lin; Chun-Yi Wu; Yen-Tze Liu; Hsin-Hua Chen
Journal:  BMJ Open       Date:  2022-10-14       Impact factor: 3.006

2.  Impact of electronic cigarette ever use on lung function in adults aged 45-85: a cross-sectional analysis from the Canadian Longitudinal Study on Aging.

Authors:  Divya Joshi; MyLinh Duong; Susan Kirkland; Parminder Raina
Journal:  BMJ Open       Date:  2021-10-27       Impact factor: 3.006

3.  Factors Associated with Quit Intentions among Adult Smokers in South Korea: Findings from the 2020 ITC Korea Survey.

Authors:  Minjung Han; Donghee Seo; Yeol Kim; Hong Gwan Seo; Sung-Il Cho; Sungkyu Lee; Sujin Lim; Susan C Kaai; Anne C K Quah; Mi Yan; Steve S Xu; Geoffrey T Fong
Journal:  Int J Environ Res Public Health       Date:  2022-08-31       Impact factor: 4.614

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.